ArticleScientific reports2021
Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Urine sample for HPV detection in men: is it a valid and non-invasive diagnostic alternative?Microbiology spectrum · 2026Article
- Comparison of urine and semen samples for HPV detection: a cross-sectional study in fertility clinic patients.Journal of clinical microbiology · 2025Article
- Adverse events following 9-valent human papillomavirus vaccine (GARDASIL® 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015-2024.Human vaccines & immunotherapeutics · 2025Article
- Prevalence and distribution of human papillomavirus in genital warts in Can Tho City, Vietnam: a cross-sectional study.Infectious agents and cancer · 2025Article
- Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania.Current oncology (Toronto, Ont.) · 2025Article
- Inflammatory Pseudotumor of the Anal Canal Mimicking Colorectal Cancer: Case Report and Hints to Improve a Patient's Fitness for Treatment and Prevention.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Organizational barriers in HPV vaccination uptake: A cross-sectional study among health sciences students.PloS one · 2025Article
- Prevalence and genotype distribution of human papillomavirus infection among Kurdish people, Iran.SAGE open medicine · 2025Article
- Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study.Human vaccines & immunotherapeutics · 2024Article
- Papillomavirus infection and male infertility: A systematic review and meta-analysis.Health science reports · 2024Review
- Human Papillomavirus and Male Infertility: What Do We Know?International journal of molecular sciences · 2023Review
- Mothers' intention to vaccinate their daughters against human papillomavirus in NorthWest Ethiopia, using the theory of planned behavior.Human vaccines & immunotherapeutics · 2023Article
- Review
- Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines.Vaccines · 2023Article
- Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania.Diagnostics (Basel, Switzerland) · 2023Article
- Sexual behavioral factors of the subjects visiting the clinic of sexually transmitted infections in Northern Finland: A cross-sectional study among 775 subjects.Health science reports · 2023Article
- Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization.Vaccines · 2023Article
- Genotype profiles of high-risk human papillomavirus in women of reproductive age: A community-based study.PloS one · 2023Article
- Human Papillomavirus (HPV) Infection and Its Impact on Male Infertility.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine compared to quadrivalent in male living in Sicily (Italy). 58.7% of samples were HPV positive and forty-four types of HPV were identified. A significant higher estimated coverage of nonavalent vaccine than quadrivalent was observed (64.3% vs. 45.8%), with absolute and relative additional impact of 20.1% and 47.2%, respectively. Low impact of the vaccine were calculated as the empirical probability of HPV genotypes 6/11/16/18/31/33/45/52/58 alone or in combination; the high impact as empirical probability of HPV6/11/16/18/31/33/45/52/58 genotypes alone or in association with other genotypes. The potential impact of the nonavalent vaccine vs quadrivalent was significant for low and high impact (29.7% > 18:8%; 34:6% > 26.6%, respectively). Particularly, in men with lesions and risky sexual contact was significant only for low impact (35.5% > 29.7%; 31.4% > 19.7%, respectively). In partners with positive females was significant for low impact (26.3% > 15.1%) and high impact (33.7% > 23.2%). Nonavalent vaccine offers broader protection in men with HPV positive partners, who would have a potential role in the transmission of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.